SIROCCO
2016
Benralizumab in Severe Eosinophilic Asthma
In 1,205 patients with severe eosinophilic asthma on high-dose ICS/LABA, benralizumab 30 mg every 4 or 8 weeks reduced annual exacerbation rate compared with placebo.
Result
Primary endpoint: Annual exacerbation rate
Exacerbation rate ratio 0.55 (95% CI 0.42–0.71) Q4W and 0.49 (0.37–0.64) Q8W, both p<0.0001; FEV1 improved.
- Subtopic
- Anti-IL-5Rα biologic
- Design
- Multicentre phase-3 RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ERS/ATS 2020 Severe Asthma
- Source
- Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.doi 10.1016/S0140-6736(16)31324-1
Discussion & critique
With CALIMA, established benralizumab for severe eosinophilic asthma.